Merrimack Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2008
Net Income	-1.18	-1.54	-2.46	-3.03	-17.33	-40.51	472.03	-151.74	-147.96	-83.29	Upgrade
Depreciation & Amortization	0	0	0	0	2.23	4.07	5.22	4.9	3.25	3.22	Upgrade
Share-Based Compensation	0.16	0.07	0.4	1.72	2.37	3.05	12.79	12.14	13.16	13.2	Upgrade
Other Operating Activities	-0.5	-0.27	1.84	-3.32	-18.64	-32.21	-615.85	-35.54	26.19	32.06	Upgrade
Operating Cash Flow	-1.52	-1.74	-0.22	-4.63	-31.37	-65.59	-125.81	-170.24	-105.36	-34.81	Upgrade
Capital Expenditures	0	0	0	0	2.03	-0.04	0.18	-2.64	-11.9	-6.04	Upgrade
Acquisitions	0.14	0.45	0.14	2.14	8.5	28	576.71	0	0	0	Upgrade
Change in Investments	-12.59	0	0	0	59.3	-50.56	0	-0.1	87.9	0.03	Upgrade
Other Investing Activities	-	-	-	-	-	-	-	-0.52	-0.89	-0	Upgrade
Investing Cash Flow	-12.45	0.45	0.14	2.14	69.83	-22.6	576.89	-3.26	75.11	-6.01	Upgrade
Dividends Paid	0	0	0	0	-26.7	0	-140	0	0	0	Upgrade
Share Issuance / Repurchase	0.52	6.53	0.24	0	0.15	0	6.92	6.22	48.65	10.38	Upgrade
Debt Issued / Paid	0	0	0	0	-15.99	14.63	-249.79	0	129.43	1.04	Upgrade
Other Financing Activities	-	-	-	-0.06	-	-	3.71	3.19	2.08	-0.01	Upgrade
Financing Cash Flow	0.52	6.53	0.24	-0.06	-42.54	14.63	-379.16	9.42	180.16	11.42	Upgrade
Net Cash Flow	-13.45	5.24	0.17	-2.54	-4.08	-73.55	71.92	-164.08	149.92	-29.4	Upgrade
Free Cash Flow	-1.52	-1.74	-0.22	-4.63	-29.34	-65.63	-125.63	-172.88	-117.26	-40.84	Upgrade
Free Cash Flow Margin	-	-	-	-	-	-	-	-	-	-39.75%	Upgrade
Free Cash Flow Per Share	-0.11	-0.13	-0.02	-0.35	-2.20	-4.92	-9.49	-13.79	-10.53	-3.91	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).